NCT06660654
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Active, Not Recruiting
PHASE2Ages 18+InterventionalTreatmentDaiichi Sankyo
~200 participants
Updated 2026-05-29 on ClinicalTrials.gov
What's tested:Raludotatug deruxtecan
At a glance
Recruiting sites
0 of 48 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Objective Response Rate as Assessed by the Investigator (All Cohorts Except ccRCC)
Measured over Baseline up to 32 months
+2 more outcomes measured
Conditions
Where it's being run
48 sites across 14 statesFrance9
Japan8
Italy7
Spain7
South Korea4
New York3
Belgium2
China2
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Objective Response Rate as Assessed by the Investigator (All Cohorts Except ccRCC)Baseline up to 32 months
Objective response rate (ORR) is defined as the proportion of participants with a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST version 1.1 criteria.
- Disease Control Rate (DCR) as Assessed by the Investigator (ccRCC Cohort Only)Baseline up to 32 months
Disease control rate (DCR) is defined as proportion of participants who achieved a BOR of confirmed CR, confirmed PR, or stable disease (maintained for ≥5 weeks) according to RECIST version 1.1.
- Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs) (All Cohorts)Baseline up to 32 months